Protein Kinases as Targets for Opisthorchis viverrini- Associated Cholangiocarcinoma Therapy

Watcharin Loilome1,2,3, Hasaya Dokduang2,3

  • 1Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Insights

Protein kinases regulate cell signaling and are implicated in cancer. This review explores protein kinases in cholangiocarcinoma (CCA) and evaluates kinase inhibitors as potential targeted therapies for this challenging cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protein kinases are crucial enzymes regulating cellular signaling pathways.
  • Aberrant kinase activity is a hallmark of various cancers, including cholangiocarcinoma (CCA).
  • CCA is a significant public health concern, particularly in northeastern Thailand, with limited treatment options.

Purpose of the Study:

  • To review the role of protein kinases in cholangiocarcinoma (CCA) development and progression.
  • To explore the potential of targeting protein kinases as a therapeutic strategy for CCA.
  • To summarize preclinical data on kinase inhibitors evaluated for CCA treatment.

Main Methods:

  • Literature review of studies on protein kinases in CCA.
  • Analysis of aberrant kinase expression, activation, and function in CCA.
  • Evaluation of preclinical data for kinase inhibitors in CCA models.

Main Results:

  • Protein kinases play significant roles in CCA carcinogenesis and progression.
  • Specific kinases are dysregulated in CCA, presenting potential therapeutic targets.
  • Preclinical studies show promise for certain kinase inhibitors in CCA treatment.

Conclusions:

  • Targeting protein kinases offers a promising avenue for novel CCA therapies.
  • Further research and clinical trials are needed to validate kinase inhibitors for CCA.
  • Understanding kinase signaling in CCA is essential for developing effective treatment strategies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K